Search Close


Interim Results for the six month period to 31 October 2011

30th January 2012

Scancell Holdings plc (“Scancell” or the “Company” or the “Group”), the developer of therapeutic cancer and infectious disease vaccines based on its patented Immunobody® platform, is pleased to announce the interim results for the six month period ended 31st October 2011.


  • Sub-division of share capital and Placing to raise £1.73 million;
  • Development of new vaccine candidate for the treatment of lung cancer;
  • Phase 1 clinical trial of SCIB1 proceeded to highest dose level following safety review;
  • SCIB1 patent awarded; and
  • Change of board structure.

Post Period Highlights:

  • Receipt of second tranche payment of £2.85 million in November 2011 relating to the sale of a portfolio of antibodies to Arana Therapeutics.

For further information contact:

Scancell Holdings Plc
Dr Richard Goodfellow / Professor Lindy Durrant
=44 (0) 20 7653 9842*

Newgate Threadneedle (Financial PR)
Guy McDougall / Heather Armstrong
+44 (0) 20 7653 9842

Zeus Capital - Nominated Adviser / Joint Broker
Ross Andrews / Tow Rowley
+44 (0) 161 831 1512

XCAP - Joint Broker
Jon Belliss / Adrian Kirk
+44 (0) 207 101 7070

*calls to this number will reach Newgate Threadneedle at Scancell's instruction.

View the full results 

Webcasts, Interviews and Media Coverage

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

Mon, 20 May 2019 09:51:00